Acute movement disorders in the medical setting: A case series, neurophysiological model, and literature review

International Journal of Psychiatry in Medicine

Volumn 51, Issue 5, 2016, Pages 395-413

  Zawar, Ifrah ^a   Caro, Mario A ^a   Feldman, Lara ^a   Jimenez, Xavier F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

basal ganglia; catatonia; consultation psychiatry; frontal subcortical; movement disorders; psychosomatic medicine

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; AMPA RECEPTOR; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CARBIDOPA; CLONAZEPAM; COTRIMOXAZOLE; CREATINE KINASE; DIAZEPAM; DOMPERIDONE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; LEVODOPA; LORAZEPAM; MELATONIN; METOCLOPRAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; ONDANSETRON; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; RITUXIMAB; SULFAMETHOXAZOLE; TETRABENAZINE; VALPROIC ACID; ZOLPIDEM;

ACUTE CONFUSION; ADULT; AGED; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; BASAL GANGLION; BEDTIME DOSAGE; CASE REPORT; DEGENERATIVE DISEASE; DELIRIUM; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FEMALE; GABAERGIC SYSTEM; HUMAN; MALE; MORNING DOSAGE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCLONUS EPILEPSY; NAUSEA; NERVOUS SYSTEM INFLAMMATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; POLYPHARMACY; RESTLESSNESS; SEIZURE; FRONTAL LOBE; NERVE CELL NETWORK; PATHOPHYSIOLOGY; PHENOTYPE; PSYCHOSOMATICS;

BASAL GANGLIA; FRONTAL LOBE; HUMANS; MOVEMENT DISORDERS; NERVE NET; PHENOTYPE; PSYCHOSOMATIC MEDICINE;

EID: 85006380606     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.1177/0091217416680202     Document Type: Article

References (86)

1. Tekin S, Cummings JL,. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002; 53: 647-654. Doi: 10.1016/S0022-3999(02)00428-2.
2. Messulam MM,. Principles of behavioral and cognitive neurology, 2nd ed. New York, NY: Oxford University Press, 2000.
3. Stoessl AJ, Lehericy S, Strafella AP,. Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet 2014; 384: 532-544. Doi: 10.1016/S0140-6736(14)60041-6.
4. Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson's disease. Lancet Lond Engl 1997; 349: 1222-1223. Doi: 10.1016/S0140-6736(05)62416-6.
5. Menza MA, Murray GB, Holmes VF, et al. Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung J Crit Care 1988; 17: 238-241.
6. Gagrat D, Hamilton J, Belmaker RH,. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978; 135: 1232-1233.
7. Ferris RM, Cooper BR, Maxwell RA,. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 1983; 44 (5 Pt 2): 74-78.
8. Wang HY, Chou WJ, Huang TY, et al. Acute dystonia resulting from abrupt bupropion discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 766-768. Doi: 10.1016/j.pnpbp.2006.12.003.
9. Mrak RE, Griffin WST,. Dementia with Lewy bodies: definition, diagnosis, and pathogenic relationship to Alzheimer's disease. Neuropsychiatr Dis Treat 2007; 3: 619-625.
10. Neef D, Walling AD,. Dementia with Lewy bodies: an emerging disease. Am Fam Physician 2006; 73: 1223-1229.
11. Stinton C, McKeith I, Taylor J-P, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 2015; 172: 731-742. Doi: 10.1176/appi.ajp.2015.14121582.
12. Warren JD, Rohrer JD, Rossor MN,. Frontotemporal dementia. The BMJ 2013; 347: f4827. Doi: 10.1136/bmj.f4827.
13. Czarnecki K, Kumar N, Josephs KA,. Parkinsonism and tardive antecollis in frontotemporal dementia-increased sensitivity to newer antipsychotics? Eur J Neurol 2008; 15: 199-201. Doi: 10.1111/j.1468-1331.2007.02032.x.
14. Lauterbach EC, Kuppuswamy PS, Greenway LL,. Differential pharmacological responses of catatonia-like signs in frontotemporal dementia. Neurocase 2010; 16: 436-450. Doi: 10.1080/13554791003623326.
15. Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. Am J Neuroradiol 2006; 27: 1459-1462.
16. Brown P, Cathala F, Castaigne P, et al. Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986; 20: 597-602. Doi: 10.1002/ana.410200507.
17. Zeidler M, Stewart G, Barraclough C, et al. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet 1997; 350: 903-907. Doi: 10.1016/S0140-6736(97)07472-2.
18. Thompson A, MacKay A, Rudge P, et al. Behavioral and psychiatric symptoms in Prion disease. Am J Psychiatry 2014; 171: 265-274. Doi: 10.1176/appi.ajp.2013.12111460.
19. Mittal SK, Eddy C,. The role of dopamine and glutamate modulation in Huntington disease. Behav Neurol 2013; 26: 255-263. Doi: 10.3233/BEN-2012-120268.
20. Pidgeon C, Rickards H,. The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol 2013; 26: 245-253. Doi: 10.3233/BEN-2012-120267.
21. Caine ED, Shoulson I,. Psychiatric syndromes in Huntington's disease. Am J Psychiatry 1983; 140: 728-733. Doi: 10.1176/ajp.140.6.728.
22. Levenson JL,. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-1145. Doi: 10.1176/ajp.142.10.1137.
23. Gahr M, Orth M, Abler B,. Neuroleptic malignant syndrome with aripiprazole in Huntington's disease. Mov Disord 2010; 25: 2475-2476. Doi: 10.1002/mds.23332.
24. Vendrame M, Azizi SA,. Pyramidal and extrapyramidal dysfunction as a sequela of hypoxic injury: case report. BMC Neurol 2007; 7: 18. Doi: 10.1186/1471-2377-7-18.
25. Bakshi R, Benedict RB, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002; 59: 62-68. Doi: 10.1001/archneur.59.1.62.
26. Mathews M, Gratz S, Adetunji B, et al. Antipsychotic-induced movement disorders. Psychiatry Edgmont 2005; 2: 36-41.
27. Davids E, Hartwig U, Gastpar M,. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 743-744. Doi: 10.1016/j.pnpbp.2004.05.010.
28. Das SK, Ray K,. Wilson's disease: an update. Nat Clin Pract Neurol 2006; 2: 482-493. Doi: 10.1038/ncpneuro0291.
29. Srinivas K, Sinha S, Taly AB, et al. Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge!. J Neurol Sci 2008; 266 (1-2): 104-108. Doi: 10.1016/j.jns.2007.09.009.
30. Lee MS, Marsden CD,. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 1994; 9: 493-507. Doi: 10.1002/mds.870090502.
31. Siniscalchi A, Gallelli L, Labate A, et al. Post-stroke movement disorders: clinical manifestations and pharmacological management. Curr Neuropharmacol 2012; 10: 254-262. Doi: 10.2174/157015912803217341.
32. Schneider SA,. Neurodegenerations with brain iron accumulation. Parkinsonism Relat Disord. Doi: 10.1016/j.parkreldis.2015.08.012.
33. Morphy MA, Feldman JA, Kilburn G,. Hallervorden-Spatz disease in a psychiatric setting. J Clin Psychiatry 1989; 50: 66-68.
34. Sunwoo Y-K, Lee J-S, Kim W-H, et al. Psychiatric disorder in two siblings with Hallervorden-Spatz disease. Psychiatry Investig 2009; 6: 226-229. Doi: 10.4306/pi.2009.6.3.226.
35. Pawar Y, Kalra G, Sonavane S, et al. A case of Hallervorden-Spatz disease presenting as catatonic schizophrenia. Indian J Psychiatry 2013; 55: 386-389. Doi: 10.4103/0019-5545.120553.
36. Panzer J, Dalmau J,. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol 2011; 24: 346-353. Doi: 10.1097/WCO.0b013e328347b307.
37. Baizabal-Carvallo JF, Jankovic J,. Movement disorders in autoimmune diseases. Mov Disord 2012; 27: 935-946. Doi: 10.1002/mds.25011.
38. Donaghy PC, McKeith IG,. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther 2014; 6: 46. Doi: 10.1186/alzrt274.
39. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872. Doi: 10.1212/01.wnl.0000187889.17253.b1.
40. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999; 122: 1449-1468. Doi: 10.1093/brain/122.8.1449.
41. Goldman JG, Goetz CG, Brandabur M, et al. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008; 23: 2248-2250. Doi: 10.1002/mds.22322.
42. Azzam PN, Gopalan P,. Prototypes of catatonia: diagnostic and therapeutic challenges in the general hospital. Psychosomatics 2013; 54: 88-93. Doi: 10.1016/j.psym.2012.06.008.
43. Tandon R, Heckers S, Bustillo J, et al. Catatonia in DSM-5. Schizophr Res 2013; 150: 26-30. Doi: 10.1016/j.schres.2013.04.034.
44. Dhossche DM, Stoppelbein L, Rout UK,. Etiopathogenesis of catatonia: generalizations and working hypotheses. J ECT 2010; 26: 253-258. Doi: 10.1097/YCT.0b013e3181fbf96d.
45. Jaimes-Albornoz W, Serra-Mestres J,. Prevalence and clinical correlations of catatonia in older adults referred to a liaison psychiatry service in a general hospital. Gen Hosp Psychiatry 2013; 35: 512-516. Doi: 10.1016/j.genhosppsych.2013.04.009.
46. Saddawi-Konefka D, Berg SM, Nejad SH, et al. Catatonia in the ICU: an important and underdiagnosed cause of altered mental status. A case series and review of the literature. Crit Care Med 2014; 42: e234-241. Doi: 10.1097/CCM.0000000000000053.
47. Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007; 19: 406-412. Doi: 10.1176/appi.neuropsych.19.4.406.
48. Dunlop BW, Nemeroff CB,. THe role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-337. Doi: 10.1001/archpsyc.64.3.327.
49. Lambert G, Johansson M, Ågren H, et al. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000; 57: 787-793. Doi: 10.1001/archpsyc.57.8.787.
50. Brambilla P, Perez J, Barale F, et al. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003; 8: 721-737. Doi: 10.1038/sj.mp.4001362.
51. Kayser MS, Dalmau J,. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res 2016; 176: 36-40. Doi: 10.1016/j.schres.2014.10.007.
52. Maneta E, Garcia G,. Psychiatric manifestations of anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications. Psychosomatics 2014; 55: 37-44. Doi: 10.1016/j.psym.2013.06.002.
53. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74. Doi: 10.1016/S1474-4422(10)70253-2.
54. Kruse JL, Jeffrey JK, Davis MC, et al. Anti-N-methyl-D-aspartate receptor encephalitis: a targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr 2014; 26: 111-119.
55. Kuppuswamy PS, Takala CR, Sola CL,. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. Gen Hosp Psychiatry 2014; 36: 388-391. Doi: 10.1016/j.genhosppsych.2014.02.010.
56. Vincent A, Bien CG, Irani SR, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-772. Doi: 10.1016/S1474-4422(11)70096-5.
57. Lee JWY,. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 2010; 30: 3-10. Doi: 10.1097/JCP.0b013e3181c9bfe6.
58. Ho JM-W, Juurlink DN,. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ Can Med Assoc J 2011; 183: 1851-1858. Doi: 10.1503/cmaj.111152.
59. Woody RC, Brewster MA,. Adverse effects of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency. Dev Med Child Neurol 1990; 32: 639-642.
60. Floris-Moore MA, Amodio-Groton MI, Catalano MT,. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother 2003; 37: 1810-1813. Doi: 10.1345/aph.1D179.
61. Aboulafia DM,. Tremors associated with trimethoprim-sulfamethoxazole therapy in a patient with AIDS: case report and review. Clin Infect Dis 1996; 22: 598-600. Doi: 10.1093/clinids/22.3.598.
62. Borucki MJ, Matzke DS, Pollard RB,. Tremor induced by trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 77-78. Doi: 10.7326/0003-4819-109-1-77.
63. Bua J, Marchetti F, Barbi E, et al. Tremors and chorea induced by trimethoprim-sulfamethoxazole in a child with Pneumocystis pneumonia. Pediatr Infect Dis J 2005; 24: 934-935.
64. de Arce Borda AM, Goenaga Sánchez MA,. Tremor produced by trimethoprim-sulfamethoxazole. Neurol Barc Spain 2000; 15: 264-265.
65. Dib EG, Bernstein S, Benesch C,. Multifocal myoclonus induced by trimethoprim-sulfamethoxazole therapy in a patient with nocardia infection. N Engl J Med 2004; 350: 88-89. Doi: 10.1056/NEJM200401013500121.
66. Jundt F, Lempert T, Dörken B, et al. Trimethoprim-sulfamethoxazole exacerbates posthypoxic action myoclonus in a patient with suspicion of pneumocystis jiroveci. Infection 2004; 32: 176-178. Doi: 10.1007/s15010-004-3011-6.
67. Patterson RG, Couchenour RL,. Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patient. Pharmacother J Hum Pharmacol Drug Ther 1999; 19: 1456-1458. Doi: 10.1592/phco.19.18.1456.30903.
68. Ross RT,. Young age parkinsonism and common drugs. Can J Neurol Sci J Can Sci Neurol 1989; 16: 366-367.
69. Van Gerpen JA,. Tremor caused by trimethoprim-sulfamethoxazole in a patient with AIDS. Neurology 1997; 48: 537-538.
70. Calva-Mercado MP, Maunoury C, Rethoré MO, et al. Fragility of the X chromosome and inhibition of dihydrofolate reductase. Comparison of the effects of 2 antibiotics: trimethoprim and pyrimethamine. Ann Génétique 1983; 26: 147-149.
71. Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004; 19: 379-390.
72. Rao AS, Camilleri M,. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31: 11-19. Doi: 10.1111/j.1365-2036.2009.04189.x.
73. Ferrando SJ, Eisendrath SJ,. Adverse neuropsychiatric effects of dopamine antagonist medications: misdiagnosis in the medical setting. Psychosomatics 1991; 32: 426-432. Doi: 10.1016/S0033-3182(91)72046-X.
74. Ben-Pazi H, Stoner JA, Cunningham MW,. Dopamine receptor autoantibodies correlate with symptoms in Sydenham's Chorea. PLoS ONE 2013; 8: e73516. Doi: 10.1371/journal.pone.0073516.
75. Martino D, Giovannoni G,. Antibasal ganglia antibodies and their relevance to movement disorders. Curr Opin Neurol 2004; 17: 425-432.
76. Burkhard PR,. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014; 20 (Supplement 1): S108-S112. Doi: 10.1016/S1353-8020(13)70027-0.
77. Boyer EW, Shannon M,. The serotonin syndrome. N Engl J Med 2005; 352: 1112-1120. Doi: 10.1056/NEJMra041867.
78. Jiménez-Jiménez FJ, García-Ruiz PJ, Molina JA,. Drug-induced movement disorders. Drug Saf 1997; 16: 180-204.
79. Gardos G, Cole JO, Tarsy D,. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978; 135: 1321-1324.
80. Herz DM, Haagensen BN, Christensen MS, et al. Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain 2015; 138: 1658-1666. Doi: 10.1093/brain/awv096.
81. Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007; 78: 147-151. Doi: 10.1136/jnnp.2006.100222.
82. Alexander GE, DeLong MR, Strick PL,. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381. Doi: 10.1146/annurev.ne.09.030186.002041.
83. Alexander GE, Crutcher MD, DeLong MR,. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990; 85: 119-146.
84. DeLong MR, Wichmann T,. CIrcuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-24. Doi: 10.1001/archneur.64.1.20.
85. Gittis AH, Kreitzer AC,. Striatal microcircuitry and movement disorders. Trends Neurosci 2012; 35: 557-564. Doi: 10.1016/j.tins.2012.06.008.
86. Jimenez XF, Azzam PN, Gopalan P,. Teaching a neuromedical-contextual approach to psychosomatic medicine. Acad Psychiatry J Am Assoc Dir Psychiatr Resid Train Assoc Acad Psychiatry 2015; 39: 204-211. Doi: 10.1007/s40596-014-0193-9.